All In Biotech

Drug Trial Radar · NCT00862459

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Multi-center, Double-blind, Randomized, Controlled, Parallel Group, Dose Comparison Study With Corresponding Blinded Image Evaluation Following a Single Intravenous Injection of Three Different Doses of Gadobutrol 1.0 Molar (Gadavist) in Patients With Known or Suspected Focal Blood Brain Barrier Disturbances and/or Abnormal Vascularity of the Central Nervous System

Last checked: Nov 20, 2026Latest source record: Jan 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 237 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

237

Actual

Start

Aug 2005

Primary completion

Mar 2007

Study completion Mar 2007

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Mar 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI with Gadavist Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with OptiMARK.

Conditions

  • Brain Diseases
  • Spinal Cord Diseases

Interventions

  • Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)Drug

    Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

  • Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)Drug

    Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

  • Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)Drug

    Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

  • OptiMARK~0.1 mmol/kg BWDrug

    Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Categorical Visualization Score (CVS)Time frame: up to 2 hours after the injection of study medication
  2. Difference in Number of Lesions Detected in Pre-contrast and Combined Pre-/Post-contrast MRI.Time frame: up to 2 hours after the injection of study medication
  3. Assessment of Lesion Contrast EnhancementTime frame: up to 2 hours after the injection of study medication
  4. Assessment of Border DelineationTime frame: up to 2 hours after the injection of study medication
  5. Assessment of Internal MorphologyTime frame: up to 2 hours after the injection of study medication
  6. Contrast to Noise Ratio (CNR) Between White and Gray Matter With Gadobutrol Perfusion MRITime frame: up to 2 hours after the injection of study medication

Locations

27 sites in 4 countries. Site status is shown where the registry gives one.

  • University of California Davis Medical Center

    Sacramento, California

  • University of California-San Diego Medical Center

    San Diego, California

  • Shands Jacksonville Medical Center

    Jacksonville, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Indiana Neuroscience Institute

    Indianapolis, Indiana

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Boston Medical Center

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Methodist Hospital

    Omaha, Nebraska

  • NYU Langone Medical Center

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center Health System

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Medical University of South Carolina

    Charleston, South Carolina

  • Methodist Le Bonheur Healthcare

    Memphis, Tennessee

  • University of Washington Medical Center

    Seattle, Washington

  • University of Wisconsin - Madison

    Madison, Wisconsin

  • TCba Salguero

    Buenos Aires, Buenos Aires, Argentina

  • Fundacion Cientifica del Sur

    Lornas de Zamora, Buenos Aires, Argentina

  • Hospital da Beneficiência Portuguesa

    São Paulo, São Paulo, Brazil

  • Fundación Clínica Valle del Lili

    Cali, Colombia

  • Centro de Diagnostico Medico

    Medellín, Antioquia, Colombia

  • Fundación Instituto de Alta tecnología médica de Antioquia

    Medellín, Antioquia, Colombia

  • DIME Clinica Neurocardiovascular S.A.

    Cali, Valle del Cauca Department, Colombia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.